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Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
COV-2). It started from Wuhan city of China and now has become a pandemic all over the world, affecting the 
majority of countries. COVID-19 has caused 71.6 million cases worldwide till now, out of which 46.8 million 
recovered and 1.6 million died. In Pakistan, it affected 429 thousand population till now, out of which 374 
thousand recovered and 8796 precious lives were lost, making fatality rate at 2%. 
The spectrum of coronavirus disease continues to unfold as time passes. It has created health and economic crisis 
all over the world. Being a new virus means less information on behavior and a lot to learn for its immunity. It 
was assumed initially that reinfection was less likely. Once exposed, we will develop antibodies and will be safe. 
But now we have a case of Covid-19 reinfection, depicting that despite exposure and having IgG Antibody titer, 
reinfection occurred within 6 months. 
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Introduction 
 
Coronavirus Disease 2019 (COVID-19) is caused by 
Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-COV-2).1 It started from Wuhan city of China 
and now has become a pandemic all over the world, 
affecting the majority of countries.2 COVID-19 has 
caused 71.6 million cases worldwide till now, out of 
which 46.8 million recovered and 1.6 million died.3 In 
Pakistan, it affected 429 thousand population till now, 
out of which 374 thousand recovered and 8796 
precious lives were lost, making fatality rate at 2%. 4 
Recently, we documented a case of COVID-19 
reinfection in healthcare professionals despite having 
acquired and documented infection from June 2020, 
through both qualitative and quantitative antibodies of 
IgG. Bao et al,5 documented immunity in monkeys 
after primary infection of SARS CoV 2, in April 2020, 
but it remained questionable if this protection will 
persist in humans.  Roy et al6 documented 3 cases of 
reinfection, with CT changes, when their PCR and IgM 
were negative and IgG were positive at the time of 
discharge. The PCR was positive again at the time of 
reinfection. They also documented 80 different 
genotypic variants of this virus. 
It, therefore, makes this case report significant because 
our subject demonstrated the previous infection. The 
antibody levels were also available in between, 
suggesting a falling titer. Hence making it the first 
reinfection case report from the region to my 
knowledge, as this occurred in December 2020. 
However, it remains that cases of reinfection are 




52-year-old male, clinician by profession, had few 
Gastrointestinal symptoms in early April 2020. 
Features settled in few days. In June 2020, qualitative 
antibody titers were carried out. IgM was negative, but 
IgG was positive, suggesting exposure to Covid-19 
(Table 1). In August, his IgG levels were tested again 
quantitatively, in the hospital set up as part of research 
work being carried out, and levels were found positive 
again, but at low levels (Table 1). Considering exposed 
and developed antibodies, and no other clinical 
features, he continued to work as usual with SOP’s. 
On 4th December 2020, he developed rhinorrhea, 
excessive lacrimation, sneezing, and cough. The 
temperature was recorded up to 100 F. Since he was a 
known asthmatic, the immediate standard protocol for 
allergic asthma was initiated. On 8th December, his 
saturation started to fall, for which he reported in 
emergency immediately.  
Other than asthma, he did not have any history of 
Diabetes, Hypertension, Smoking, surgery, or any 
other habituation. However, being on the clinical side, 
his exposure to Covid-19 patients was very strong. The 
usual protection of mask and hand sanitization was 




It was worth noting that the Neutrophil lymphocyte 
ratio (NLR) was 3.409 at admission, and later 
increased during illness, since methylprednisolone 
was started. Inflammatory markers like CRP were 
reduced from 111 to 52 and 12.5 at discharge. Ferritin 
increased from 551.7 to 581.7 and 620. LDH reduced 
from 781 to 525 and 382. IgG antibody level which was 
1.5 in August 2020, rose to 9 on the second day of 
admission, and 12 at the time of discharge. RT-PCR 
was positive from the time of admission. A high IgG 
antibody titer within few days of acquiring fresh 
COVID-19 infection was indicative of memory cells 
from previous exposure, yet not able to prevent it. D-
dimer levels remained normal throughout (Table 2). 



























Hemoglobin 16.5 15.8 16.7 
WBC 9.1 15.1 13.2 
Platelet 152 198 300 
N 75 92 89 
L 22 5 10 
E 1 0 0 
B 2 3 1 
Bilirubin 0.80 0.8 0.81 
SGPT 38 33 68 
SGOT 35 37 42 
Alkaline P04 323 242 286 
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Serum 
Sodium 
  139 
Serum 
Potassium 
  4.1 
Uric Acid  6.3  
BSR 154 160 223 
HCT 51.2 47.8 50.98 
Urea 29 76 68 
Creatinine 1.1 1.4 1.3 
Calcium  9.5  
CRP 111.7 52.4 12.5 
Ferritin 551.7 581.7 620 
LDH 784 525 352 










Positive   
CPK  156  
HRCT Chest Report Dated 08.12.2020:  
Areas of consolidation with air bronchograms in the 
right upper and lower lobe and left lower lobe apical 
segment, mainly peripheral distribution. Also patchy 
peripheral, subpleural areas of ground-glass opacities 
were appreciated in both upper and lower lobes. No 
pleural effusion was seen on either side. No 
bronchiectasis or fibrotic changes were seen on either 
side.  
The final Impression was that CT features were of 
bilateral patchy areas of consolidation and ground-






















Is it possible to get immunity against Covid-19 
infection? The question remains unanswered. We had 
learned a lot during this one year of pandemic, but is it 
all? Or there is still more to catch up on?  
Madan and Kunal7 wrote in a letter to the editor 
regarding reinfection or relapse of COVID-19 
infection. Their dissatisfaction over the conclusion was 
based on multiple factors including pre and post 
COVID-19 features comparison. Our case report has 
addressed that part, as our patient had already 
documented laboratory positive parameters. Although 
these titers were falling, with reinfection, there was a 
significant rise with positive PCR and radiological and 
biochemical evidence. HRCT and PCR were alone 
sufficient to confirm reinfection, but a sudden rise in 
antibody titer further confirmed a second infection. It 
remained questionable, if it was the reactivation of 
previous infection, or a new variant, which requires 
more clinical research. 
Jeyanathan et al8 have documented that the 
development of immunity to a pathogen through 
natural infection is a multi step process that can take 
weeks. The body responds immediately with a non-
specific innate response by macrophages and 
neutrophils which are followed by an adaptive 
response that makes antibodies that specifically binds 
to Virus spike proteins. Later T-cells recognize and 
eliminate other infected cells (cellular immune 
response). So, following COVID-19 infection, 
Immunoglobulins should be formed and immunity to 
further reinfection should be present. But it is novel to 
COVID-19 that we have reported reinfection despite 
being positive for immunoglobulins.  
So, firstly, this behavior of virus has to be studied and 
researched, that whether every infected person mounts 
an immune response and how long protective 
immunity will last? (How long and how strong 
protection is?). Animal studies indicated a protective 
response to reinfection. It is yet to be established that 
how much antibody titer is protective for the 
prevention of reinfection.9 
Secondly, is there a new strain of virus in circulation in 
our population? Or virus has mutated? This should be 
researched whether Reinfection occurred with the 
same strain of virus or with a different strain.10 
Thirdly, laboratory tests need further validation 
including a rapid immunodiagnostic tests for accuracy 
and reliability. There is a need to distinguish between 
past infection of COVID-19 and other six known 
human coronaviruses out of which four cause common 
colds and circulate widely.11 These viruses may 
produce antibodies that cross-react with antibodies 




Currently, there is not enough evidence of antibody-
mediated immunity. Our case may be a case of 
COVID-19 reinfection. So, personal protection and 
preventive measures remain primary preventive 
methods. Reliability, accuracy, and protection from the 
presence of Antibodies have to be established. Also, 
this case report raises the question on vaccination of 
different types, relying on the development of IgG 
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